Identification of Family with Sequence Similarity 110 Member C (FAM110C) as a Candidate Diagnostic and Prognostic Biomarker for Glioma

Deshuai  Ren; Xiaoyu  Zhuang; Yanxin  Lv; Yun  Zhang; Jiazhi  Xu; Fengquan  Gao; Dagang  Chen; Yu  Wang

doi:10.18502/ijph.v52i10.13850

Deshuai Ren Department of Neurosurgery, the Third Affiliated Hospital of Qiqihar Medical University, Qiqihar 162400, China
Xiaoyu Zhuang Hospital Chief Office, Tailai People's Hospital, Qiqihar 161000, China
Yanxin Lv Basic Medicine Department, Qiqihar Medical University, Qiqihar 161006, China
Yun Zhang Department of Neurosurgery, the Third Affiliated Hospital of Qiqihar Medical University, Qiqihar 162400, China
Jiazhi Xu Department of Neurosurgery, the Third Affiliated Hospital of Qiqihar Medical University, Qiqihar 162400, China
Fengquan Gao Department of Neurosurgery, the Third Affiliated Hospital of Qiqihar Medical University, Qiqihar 162400, China
Dagang Chen Department of Neurosurgery, the Third Affiliated Hospital of Qiqihar Medical University, Qiqihar 162400, China
Yu Wang Basic Medicine Department, Qiqihar Medical University, Qiqihar 161006, China

DOI: https://doi.org/10.18502/ijph.v52i10.13850

Keywords: Glioma; Biomarkers; Molecular targets; Prognosis

Abstract

Background: Gliomas are the most frequent and dangerous primary cerebral tumors. Therefore, there is a need to develop molecular targets for the diagnosis and treatment for glioma.

Methods: In September 2020, we retrieved the expression matrix of glioblastoma (GBM) sufferers and pertinent clinical data from the TCGA (The Cancer Genome Atlas) database. Prognostic differences between various families with sequence similarity 110 member C (FAM110C) expression groups were assessed by Kaplan-Meier with log-rank test. The R platform get used to assess the accuracy of FAM110C delivery in predicting the prognosis of PDAC using a time-dependent receptor operating characteristic (ROC) curve. The delivery level of FAM110C was determined by qRT-PCR and western blot. Gene set enrichment investigated possible mechanisms between different FAM110C expression groups in GBM (GSEA). The impact of FAM110C on glioma cell movement was discovered using migration test. The drug's gene-targeting impact was validated by the CCK8 test.

Results: A total of 173 GBM samples were obtained from the TCGA database, with 148 including information on IDH1 mutations and 151 containing information on overall survival. The mRNA expression level of FAM110C was greater in wild-type GBM, according to qRT-PCR data. The connection between FAM110C expression and Hallmark, GO, and KEGG pathway gene sets was investigated using GSEA software. We used migration test to assess the impact of FAM110C on glioma motility in order to confirm the findings of the GSEA analysis.

Conclusion: FAM110C might get used as a possible diagnostic and prognostic biomarker for wild-type GBM, and its inhibition could be used to prevention and treatment wild-type GBM.